SB010

DRUG4 trials

Sponsors

Sterna Biologicals GmbH & Co. KG

Conditions

Asthma

Phase 1

Safety, Tolerability, and Pharmacokinetics of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects

CompletedNCT01470911

Sterna Biologicals GmbH & Co. KGAsthma

Start: 2011-11-30End: 2011-12-31Updated: 2012-11-22

Safety, Tolerability, and Pharmacokinetics After Multiple Doses of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects

CompletedNCT01554319

Sterna Biologicals GmbH & Co. KGAsthma

Start: 2012-04-30End: 2012-08-31Updated: 2012-11-27

Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma

CompletedNCT01577953

Sterna Biologicals GmbH & Co. KGAsthma

Start: 2012-04-30End: 2012-08-31Updated: 2014-04-29

Phase 2

Safety, Efficacy, PK, and PD Characteristics of Orally Inhaled SB010 in Male Patients With Mild Asthma (Multiple Dose)

CompletedNCT01743768

Sterna Biologicals GmbH & Co. KGAsthma

Start: 2012-12-31End: 2013-12-31Updated: 2015-05-20

Related Papers

Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme

New England Journal of Medicine2015-05-17313 citations